Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.56 |
| ▸ | AOC3 | Q16853 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | CASR | P41180 | 3/20 | 0.50 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30617765 | 1.00 | TAAR1 (0.56) | TAAR1AOC3ALDH1A1CYP3A4L3MBTL1 | |
| SCHEMBL135107 | 1.00 | TAAR1 (0.56) | TAAR1AOC3ALDH1A1CYP3A4L3MBTL1 | |
| SCHEMBL29676707 | 1.00 | TAAR1 (0.56) | TAAR1AOC3ALDH1A1CYP3A4L3MBTL1 | |
| SCHEMBL335349 | 1.00 | TAAR1 (0.56) | TAAR1AOC3ALDH1A1CYP3A4L3MBTL1 | |
| SCHEMBL29350839 | 1.00 | TAAR1 (0.56) | TAAR1AOC3ALDH1A1CYP3A4L3MBTL1 | |
| Hydrochloric Acid SCHEMBL16345210 | 0.98 | TAAR1 (0.55) | TAAR1AOC3ALDH1A1CYP3A4L3MBTL1 | |
| Hydrochloric Acid SCHEMBL12495550 | 0.98 | TAAR1 (0.55) | TAAR1AOC3ALDH1A1CYP3A4L3MBTL1 | |
| SCHEMBL10781087 | 0.85 | AOC3 (0.54) | TAAR1AOC3ALDH1A1CYP3A4L3MBTL1 | |
| SCHEMBL10781776 | 0.85 | AOC3 (0.54) | TAAR1AOC3ALDH1A1CYP3A4L3MBTL1 | |
| SCHEMBL8204131 | 0.84 | TAAR1 (0.53) | TAAR1AOC3ALDH1A1CYP3A4L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 477 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250078176-A1 | ENVIRONMENTAL ATTRIBUTES FOR NITROGEN CONTAINING CHEMICALS | BASF SE (DE) | 2025-03-06 | — | — | US | claimed |
| CN-118435582-A | Environmental attributes of nitrogen-containing chemicals | 巴斯夫欧洲公司 | 2024-08-02 | — | — | CN | claimed |
| CN-114804989-B | Purification method and racemization recycling of rivastigmine key chiral intermediate | 华中科技大学 | 2023-12-26 | — | — | CN | claimed |
| WO-2023117926-A1 | ENVIRONMENTAL ATTRIBUTES FOR NITROGEN CONTAINING CHEMICALS | BASF SE (DE) | 2023-06-29 | — | — | WO | claimed |
| CN-114804989-A | Purification method and racemization recycling of rivastigmine key chiral intermediate | 华中科技大学 | 2022-07-29 | — | — | CN | claimed |
| EP-1773768-B1 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS INC (US) | 2018-08-22 | — | — | EP | claimed |
| US-9833768-B2 | Affinity reagents for protein purification | IMPOSSIBLE FOODS INC. (US) | 2017-12-05 | — | — | US | claimed |
| US-20170320041-A1 | AFFINITY REAGENTS FOR PROTEIN PURIFICATION | IMPOSSIBLE FOODS INC. | 2017-11-09 | — | — | US | claimed |
| US-9737875-B2 | Affinity reagents for protein purification | IMPOSSIBLE FOODS INC. (US) | 2017-08-22 | — | — | US | claimed |
| US-8084630-B2 | Process for the synthesis of ramelteon and its intermediates | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2011-12-27 | — | — | US | claimed |
| US-20090069581-A1 | PROCESS FOR THE SYNTHESIS OF RAMELTEON AND ITS INTERMEDIATES | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-03-12 | — | — | US | claimed |
| EP-1773768-A4 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS INC (US) | 2008-08-06 | — | — | EP | claimed |
| US-20080125432-A1 | 5-Carboxamido Substituted Thiazole Derivatives that Interact With Ion Channels, In Particular With Ion Channels From the Kv Family | DEVGEN NV (BE) | 2008-05-29 | — | — | US | claimed |
| EP-1819330-A1 | 5-CARBOXAMIDO SUBSTITUED THIAZOLE DERIVATIVES THAT INTERACT WITH ION CHANNELS, IN PARTICULAR WITH ION CHANNELS FROM THE KV FAMILY | Devgen N.V. (BE) | 2007-08-22 | — | — | EP | claimed |
| EP-1773768-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | Exelixis, Inc. (US) | 2007-04-18 | — | — | EP | claimed |
| WO-2006058905-A1 | 5-CARBOXAMIDO SUBSTITUTED THIAZOLE DERIVATIVES THAT INTERACT WITH ION CHANNELS, IN PARTICULAR WITH ION CHANNELS FROM THE Kv FAMILY | DEVGEN NV (BE) | 2006-06-08 | — | — | WO | claimed |
| WO-2006012642-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS, INC. (US) | 2006-02-02 | — | — | WO | claimed |
| US-5648540-A | Amine preparation | NPS PHARMACEUTICALS, INC. (US) | 1997-07-15 | — | — | US | claimed |
| US-5504253-A | Amine preparation | NPS PHARMACEUTICALS, INC. (US) | 1996-04-02 | — | — | US | claimed |
| WO-1996002492-A1 | METHOD OF MAKING A BENZYLPROPANAMINE | NSP PHARMACEUTICALS, INC. (US) | 1996-02-01 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170320041-A1 | AFFINITY REAGENTS FOR PROTEIN PURIFICATION | RAB5IF, MRPL21, RPS27A | TAAR1 4419/4885AOC3 4516/4885ALDH1A1 4248/4885 |
| US-20090069581-A1 | PROCESS FOR THE SYNTHESIS OF RAMELTEON AND ITS INTERMEDIATES | CYP2B6, UGT1A6, CYP2A6 | TAAR1 2307/4885AOC3 2448/4885ALDH1A1 1428/4885 |
| US-20080125432-A1 | 5-Carboxamido Substituted Thiazole Derivatives that Interact With Ion Channels, In Particular With Ion Channels From the Kv Family | KCNA5, KCNA1, KCNJ2 | TAAR1 543/4885AOC3 2874/4885ALDH1A1 1395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.